Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Video captures Israeli settler fatally shooting Palestinian activist in West Bank
Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Video captures Israeli settler fatally shooting Palestinian activist in West Bank